Style | Citing Format |
---|---|
MLA | Musazadeh V, et al.. "Effects of Flaxseed Supplementation on Inflammatory Biomarkers: A Grade-Assessed Systematic Review and Meta-Analysis of Randomized Controlled Trials." Prostaglandins and Other Lipid Mediators, vol. 174, no. , 2024, pp. -. |
APA | Musazadeh V, Morovatshoar R, Kavyani Z, Vajdi M, Askari G (2024). Effects of Flaxseed Supplementation on Inflammatory Biomarkers: A Grade-Assessed Systematic Review and Meta-Analysis of Randomized Controlled Trials. Prostaglandins and Other Lipid Mediators, 174(), -. |
Chicago | Musazadeh V, Morovatshoar R, Kavyani Z, Vajdi M, Askari G. "Effects of Flaxseed Supplementation on Inflammatory Biomarkers: A Grade-Assessed Systematic Review and Meta-Analysis of Randomized Controlled Trials." Prostaglandins and Other Lipid Mediators 174, no. (2024): -. |
Harvard | Musazadeh V et al. (2024) 'Effects of Flaxseed Supplementation on Inflammatory Biomarkers: A Grade-Assessed Systematic Review and Meta-Analysis of Randomized Controlled Trials', Prostaglandins and Other Lipid Mediators, 174(), pp. -. |
Vancouver | Musazadeh V, Morovatshoar R, Kavyani Z, Vajdi M, Askari G. Effects of Flaxseed Supplementation on Inflammatory Biomarkers: A Grade-Assessed Systematic Review and Meta-Analysis of Randomized Controlled Trials. Prostaglandins and Other Lipid Mediators. 2024;174():-. |
BibTex | @article{ author = {Musazadeh V and Morovatshoar R and Kavyani Z and Vajdi M and Askari G}, title = {Effects of Flaxseed Supplementation on Inflammatory Biomarkers: A Grade-Assessed Systematic Review and Meta-Analysis of Randomized Controlled Trials}, journal = {Prostaglandins and Other Lipid Mediators}, volume = {174}, number = {}, pages = {-}, year = {2024} } |
RIS | TY - JOUR AU - Musazadeh V AU - Morovatshoar R AU - Kavyani Z AU - Vajdi M AU - Askari G TI - Effects of Flaxseed Supplementation on Inflammatory Biomarkers: A Grade-Assessed Systematic Review and Meta-Analysis of Randomized Controlled Trials JO - Prostaglandins and Other Lipid Mediators VL - 174 IS - SP - EP - PY - 2024 ER - |